Reuters logo
BRIEF-La Jolla Pharmaceutical announces positive top-line results from ATHOS-3 phase 3 study of LJPC-501
February 27, 2017 / 11:16 AM / 9 months ago

BRIEF-La Jolla Pharmaceutical announces positive top-line results from ATHOS-3 phase 3 study of LJPC-501

Feb 27 (Reuters) - La Jolla Pharmaceutical Co

* La Jolla Pharmaceutical Company announces positive top-line results from ATHOS-3 phase 3 study of LJPC-501

* La Jolla Pharmaceutical Co - Primary efficacy endpoint analysis highly statistically significant

* La Jolla Pharmaceutical Co - New drug application planned for second half of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below